VarmX Heads to LSX World Congress and Bio€quity Europe: Pioneering Approaches for Reversing Anticoagulation
In April, VarmX, a biotech company focused on developing innovative approaches for reversing anticoagulation, will be attending the LSX World Congress and presenting at Bio€quity Europe. The LSX World Congress is a prominent partnering, strategy, and investment event in Europe that features 1:1 partnering opportunities. At the event, Martijn Negen, VarmX’s SVP Global Commercial Strategy & Business Development, will participate in a panel discussion.
In May, Bio€quity Europe will take place. Organized by BioCentury, this key biopartnering event for the European biotech industry has selected Martijn Negen to present at this prestigious occasion. If you wish to meet with the VarmX team or obtain more information about their upcoming events, please contact info@varmx.com.
VarmX is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, an expert in hemostasis and thrombosis. Their lead compound VMX-C001 is a modified recombinant blood factor X developed for treating severe spontaneous bleeding and preventing bleeding during urgent surgeries in patients using oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is backed by a strong group of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital
